دورية أكاديمية
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
| العنوان: | Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. |
|---|---|
| المؤلفون: | Uy GL; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA., Costa LJ; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Hari PN; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Zhang MJ; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA., Huang JX; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Anderson KC; Hematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA., Bredeson CN; The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Callander NS; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Cornell RF; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Perez MA; Servicio de Oncohematologia, Hospital Infantil Universitario Nino Jesus, Madrid, Spain., Dispenzieri A; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Freytes CO; South Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, TX, USA., Gale RP; Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK., Garfall A; Division of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Gertz MA; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Gibson J; Haematology Department, Royal Prince Alfred Hospital Institute of Haematology, Camperdown, New South Wales, Australia., Hamadani M; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Lazarus HM; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA., Kalaycio ME; Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA., Kamble RT; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA., Kharfan-Dabaja MA; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Krishnan AY; Department of Hematology/Oncology, City of Hope National Medical Center, Duarte, CA, USA., Kumar SK; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Landau HJ; Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lee CH; Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia., Maiolino A; Hospital Universitário Clementinio Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Marks DI; Pediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK., Mark TM; Department of Medicine, New York Presbyterian Hospital at Cornell, New York, NY, USA., Munker R; Section of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA., Nishihori T; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Olsson RF; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden., Ramanathan M; Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA., Rodriguez TE; Bone Marrow Transplant Program, Loyola University Medical Center, Chicago, IL, USA., Saad AA; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Schiller GJ; Bone Marrow Transplant Program, UCLA Center for Health Sciences, Los Angeles, CA, USA., Schouten HC; Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands., Schriber JR; Cancer Transplant Institute, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA.; Arizona Oncology, Scottsdale, AZ, USA., Scott E; Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA., Seo S; Department of Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Sharma M; Department of Hematology/Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Ganguly S; Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA., Stadtmauer EA; Division of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Tay J; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., To LB; Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia., Vesole DH; Hackensack University Medical Center, Hackensack, NJ, USA., Vogl DT; Division of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Wagner JL; Department of Hematology/Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Wirk B; Seattle Cancer Care Alliance, Seattle, WA, USA., Wood WA; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., D'Souza A; Center for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. |
| المصدر: | Bone marrow transplantation [Bone Marrow Transplant] 2015 Dec; Vol. 50 (12), pp. 1513-8. Date of Electronic Publication: 2015 Aug 24. |
| نوع المنشور: | Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: London : Nature Publishing Group Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986- |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*, Hematopoietic Stem Cell Mobilization/*methods , Multiple Myeloma/*blood , Multiple Myeloma/*therapy, Adolescent ; Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Platelet Count ; Prospective Studies ; Recovery of Function ; Survival Rate |
| مستخلص: | In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control. |
| References: | J Clin Apher. 2015 Jun;30(3):176-82. (PMID: 25293363) Biol Blood Marrow Transplant. 2009 Jun;15(6):718-23. (PMID: 19450756) Leukemia. 2008 Jun;22(6):1282-4. (PMID: 18216870) Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. (PMID: 18033320) Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8. (PMID: 18541199) Leukemia. 2007 Sep;21(9):2035-42. (PMID: 17581613) Clin Lymphoma Myeloma. 2006 Mar;6(5):384-8. (PMID: 16640814) Blood. 1998 Nov 1;92(9):3131-6. (PMID: 9787148) J Clin Oncol. 1998 Apr;16(4):1547-53. (PMID: 9552064) Bone Marrow Transplant. 1997 Aug;20(3):211-7. (PMID: 9257889) N Engl J Med. 1996 Jul 11;335(2):91-7. (PMID: 8649495) J Hematother. 1992 Winter;1(4):317-27. (PMID: 1285381) N Engl J Med. 2003 May 8;348(19):1875-83. (PMID: 12736280) Blood. 2009 Jun 4;113(23):5720-6. (PMID: 19363221) N Engl J Med. 2014 Sep 4;371(10):895-905. (PMID: 25184862) Leukemia. 2014 May;28(5):1122-8. (PMID: 24157580) N Engl J Med. 2012 May 10;366(19):1782-91. (PMID: 22571202) N Engl J Med. 2012 May 10;366(19):1770-81. (PMID: 22571201) Biol Blood Marrow Transplant. 2011 May;17(5):729-36. (PMID: 20813198) Bone Marrow Transplant. 2011 Apr;46(4):523-8. (PMID: 20622909) Bone Marrow Transplant. 2011 Jan;46(1):59-63. (PMID: 20421869) Blood. 2001 Oct 1;98(7):2059-64. (PMID: 11567990) Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-56. (PMID: 18721768) |
| معلومات مُعتمدة: | U10 HL069294 United States HL NHLBI NIH HHS; U24 CA076518 United States CA NCI NIH HHS; U10 HL069286 United States HL NHLBI NIH HHS; P50 CA186781 United States CA NCI NIH HHS; UL1 TR000055 United States TR NCATS NIH HHS |
| تواريخ الأحداث: | Date Created: 20150825 Date Completed: 20160912 Latest Revision: 20190610 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC4548821 |
| DOI: | 10.1038/bmt.2015.190 |
| PMID: | 26301967 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-5365 |
|---|---|
| DOI: | 10.1038/bmt.2015.190 |